Literature DB >> 3757719

Gallstone dissolution treatment with a combination of chenodeoxycholic and ursodeoxycholic acids. Studies of safety, efficacy and effects on bile lithogenicity, bile acid pool, and serum lipids.

R Roehrkasse, H Fromm, M Malavolti, A K Tunuguntla, S Ceryak.   

Abstract

Sixteen patients with radiolucent gallstones were treated with a combination of chenodeoxycholic and ursodeoxycholic acids for an average of 19 months. Liver tests remained normal in all patients. In nine of 15 patients (60%), in whom the gallbladder visualized during an oral cholecystogram, gallstones dissolved after one year, in eight of them, partially, and in the remaining one, completely. After two years, partial dissolution became complete in three patients, and partial dissolution occurred in 1 additional patient. Changes in lithogenic index and bile acid pool size were statistically not significant. Biliary content of chenodeoxycholic acid increased significantly from 25.7 +/- 3.53 to 45.2 +/- 3.31 (mean +/- SE)% and that of ursodeoxycholic acid from 2.6 +/- 0.52 to 34.6 +/- 2.45%. There were no discernible changes in serum triglycerides, total cholesterol, and HDL cholesterol. The findings suggest that the chenodeoxycholic-ursodeoxycholic acid combination provides a safe and efficacious treatment for some cholesterol gallstones.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757719     DOI: 10.1007/bf01300255

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Letter: A simple calculation of the lithogenic index of bile: expressing biliary lipid composition on rectangular coordinates.

Authors:  P J Thomas; A F Hofmann
Journal:  Gastroenterology       Date:  1973-10       Impact factor: 22.682

2.  Rapid dissolution of gallstones by methyl tert-butyl ether. Preliminary observations.

Authors:  M J Allen; T J Borody; T F Bugliosi; G R May; N F LaRusso; J L Thistle
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

3.  Calcification of radiolucent gall stone during treatment with ursodeoxycholic acid.

Authors:  M C Bateson; I A Bouchier; D B Trash; D P Maudgal; T C Northfield
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-05

4.  Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. part I.

Authors:  W H Bachrach; A F Hofmann
Journal:  Dig Dis Sci       Date:  1982-08       Impact factor: 3.199

5.  Mesophase formation during cholesterol dissolution in ursodeoxycholate-lecithin solutions: new mechanism for gallstone dissolution in humans.

Authors:  O I Corrigan; C C Su; W I Higuchi; A F Hofmann
Journal:  J Pharm Sci       Date:  1980-07       Impact factor: 3.534

6.  [Shock waves. A new therapeutic principle in medicine].

Authors:  W Brendel
Journal:  MMW Munch Med Wochenschr       Date:  1984-01-06

7.  The physical chemistry of cholesterol solubility in bile. Relationship to gallstone formation and dissolution in man.

Authors:  M C Carey; D M Small
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

8.  Chenotherapy for gallstone dissolution. I. Efficacy and safety.

Authors:  J L Thistle; A F Hofmann; B J Ott; D H Stephens
Journal:  JAMA       Date:  1978-03-13       Impact factor: 56.272

9.  Formation of ursodeoxycholic acid from chenodeoxycholic acid in the human colon: studies of the role of 7-ketolithocholic acid as an intermediate.

Authors:  H Fromm; R P Sarva; F Bazzoli
Journal:  J Lipid Res       Date:  1983-07       Impact factor: 5.922

10.  Cholesterol solubility in bile. Evidence that supersaturated bile is frequent in healthy man.

Authors:  R T Holzbach; M Marsh; M Olszewski; K Holan
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

View more
  11 in total

Review 1.  Extracorporeal biliary lithotripsy and direct chemolitholysis-an integrated concept.

Authors:  W Domschke
Journal:  Gastroenterol Jpn       Date:  1989-10

2.  Extension of selection criteria for extracorporeal shock wave lithotripsy for gall stones.

Authors:  A Darzi; J R Monson; C O'Morain; W A Tanner; F B Keane
Journal:  BMJ       Date:  1989-07-29

Review 3.  Non-surgical treatment of gall stones: many contenders but who will win the crown?

Authors:  I A Bouchier
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

4.  Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy.

Authors:  J R Walters; K A Hood; D Gleeson; J P Ellul; A Keightley; G M Murphy; R H Dowling
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

5.  Hydrophobic bile salt inhibits bacterial adhesion on biliary stent material.

Authors:  J Y Sung; E A Shaffer; K Lam; I Rususka; J W Costerton
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

6.  Cholesterol (thermodynamic) activity determinations in bile salt-lecithin-cholesterol systems and cholesterol-rich liquid crystalline mesophase formation.

Authors:  U K Jain; W I Higuchi; C L Liu; P H Lee; N A Mazer
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

7.  Ursocholic acid: bile acid and bile lipid dose response and clinical studies in patients with gall stones.

Authors:  P J Howard; D Gleeson; G M Murphy; R H Dowling
Journal:  Gut       Date:  1989-01       Impact factor: 23.059

8.  Synthesis and metabolism of sodium 3 alpha,7 alpha-dihydroxy-25,26-bishomo-5 beta-cholane-26-sulfonate in the hamster.

Authors:  T Mikami; E H Mosbach; B I Cohen; N Ayyad; M Yoshii; K Kihira; T Hoshita
Journal:  Lipids       Date:  1995-01       Impact factor: 1.880

9.  In vitro comparison of different gall stone dissolution solvents.

Authors:  H Vergunst; O T Terpstra; H G Nijs; G Steen
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

10.  Effect of laser fragmentation of cholesterol and mixed gallstones on in vitro dissolution in methyl tert-butyl ether.

Authors:  B F Smith
Journal:  Dig Dis Sci       Date:  1990-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.